Fate Therapeutics, Inc. (NASDAQ:FATE) Expected to Post Earnings of -$0.86 Per Share

Brokerages predict that Fate Therapeutics, Inc. (NASDAQ:FATEGet Rating) will post ($0.86) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Ten analysts have issued estimates for Fate Therapeutics’ earnings. The lowest EPS estimate is ($1.00) and the highest is ($0.73). Fate Therapeutics reported earnings per share of ($0.58) during the same quarter last year, which would suggest a negative year-over-year growth rate of 48.3%. The business is scheduled to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Fate Therapeutics will report full-year earnings of ($3.40) per share for the current financial year, with EPS estimates ranging from ($4.00) to ($2.91). For the next year, analysts expect that the business will report earnings of ($3.96) per share, with EPS estimates ranging from ($4.61) to ($3.07). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATEGet Rating) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.08. Fate Therapeutics had a negative return on equity of 34.89% and a negative net margin of 368.76%. The firm had revenue of $18.40 million during the quarter, compared to analysts’ expectations of $9.01 million. During the same period in the previous year, the firm posted ($0.48) EPS. Fate Therapeutics’s revenue for the quarter was up 65.2% on a year-over-year basis.

Several research analysts recently commented on the company. StockNews.com raised Fate Therapeutics to a “sell” rating in a research note on Thursday, March 24th. Wedbush boosted their target price on Fate Therapeutics from $74.00 to $77.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 1st. HC Wainwright lowered their price objective on Fate Therapeutics from $122.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, March 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Fate Therapeutics in a research report on Friday, April 1st. Finally, Truist Financial lowered their price objective on Fate Therapeutics from $125.00 to $75.00 in a research report on Wednesday, April 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $87.22.

FATE opened at $22.64 on Tuesday. Fate Therapeutics has a 12 month low of $20.49 and a 12 month high of $97.43. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -9.32 and a beta of 1.69. The business has a fifty day moving average price of $34.26 and a 200 day moving average price of $43.06.

In other Fate Therapeutics news, insider Yu-Waye Chu sold 4,062 shares of the company’s stock in a transaction that occurred on Tuesday, April 19th. The stock was sold at an average price of $35.37, for a total transaction of $143,672.94. Following the completion of the sale, the insider now directly owns 151,033 shares of the company’s stock, valued at approximately $5,342,037.21. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO J Scott Wolchko sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $35.00, for a total value of $1,050,000.00. Following the sale, the chief executive officer now directly owns 431,546 shares of the company’s stock, valued at $15,104,110. The disclosure for this sale can be found here. Insiders sold a total of 90,624 shares of company stock valued at $3,270,224 over the last three months. Company insiders own 18.58% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of FATE. Eaton Vance Management raised its stake in Fate Therapeutics by 99.6% during the 3rd quarter. Eaton Vance Management now owns 545 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 272 shares during the last quarter. Lindbrook Capital LLC raised its stake in Fate Therapeutics by 1,444.4% during the 4th quarter. Lindbrook Capital LLC now owns 556 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 520 shares during the last quarter. Concord Wealth Partners raised its stake in Fate Therapeutics by 939.8% during the 4th quarter. Concord Wealth Partners now owns 915 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 827 shares during the last quarter. Compagnie Lombard Odier SCmA purchased a new stake in Fate Therapeutics during the 1st quarter valued at approximately $70,000. Finally, Canada Pension Plan Investment Board raised its stake in Fate Therapeutics by 575.9% during the 4th quarter. Canada Pension Plan Investment Board now owns 1,994 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 1,699 shares during the last quarter.

Fate Therapeutics Company Profile (Get Rating)

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.

See Also

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.